Rankings
▼
Calendar
CTMX FY 2013 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
CTMX
CytomX Therapeutics, Inc.
$809M
FY 2013 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$888,000
Gross Profit
$888,000
100.0% margin
Operating Income
-$15M
-1684.2% margin
Net Income
-$15M
-1705.3% margin
EPS (Diluted)
$-15.32
Cash Flow
Operating Cash Flow
-$8M
Free Cash Flow
-$9M
Stock-Based Comp.
$343,000
Balance Sheet
Total Assets
$14M
Total Liabilities
$58M
Stockholders' Equity
-$44M
Cash & Equivalents
$9M
← FY 2014
All Quarters